Researchers at the University of Oklahoma have unveiled new insights into the role of amylin, a hormone involved in appetite and blood sugar regulation, potentially signaling a major advancement in obesity treatment. Their findings, published in the journal Science Signaling, offer a clearer direction for developing more effective weight loss medications.
The study’s senior author, Augen Pioszak, Ph.D., an associate professor of biochemistry and physiology, revealed key insights into the activation of amylin receptors in the brain. While these receptors share a common core component, it is their varying accessory subunits that have captured researchers’ interest. This study offers the first precise understanding of the specific actions triggered by each receptor. Following a meal, when the pancreas secretes insulin, amylin is released as well. Drugs can either bring these subunits together or separate them—a crucial aspect for those seeking to manipulate these mechanisms.
As part of a wider industrial push to develop cutting-edge obesity drugs, this clarification in the amylin receptors' behavior offers substantial promise. Acknowledging the study's progress, Pioszak told the University of Oklahoma, "This paper shows the new biochemical and pharmacological methods we developed that will enable the field, for the first time, to understand exactly what drugs in development do at each of the three amylin receptors." Significantly, these receptors are related to GLP-1 receptors, already a target for successful weight loss drugs like semaglutide.
Doctoral student Sandra Gostynska, who has played a leading role in these breakthroughs, highlighted the expanded toolkit now available to researchers, suggesting a more nuanced and sophisticated approach to how drugs interact with the amylin system. "What we have done is given the field new tools for understanding how a drug can affect amylin receptors," Gostynska said in a statement to the University of Oklahoma. The potential impact extends beyond simply curbing appetite to understanding how different accessory subunits influence the amylin receptors, enabling the development of more targeted and effective therapies.
Looking ahead, the potential benefits for pharmaceutical companies are significant. Drugmakers developing amylin-based treatments may find the path to market clearer, as Pioszak’s research provides valuable insights into drug-receptor dynamics. He expressed confidence that this work will encourage further studies, as companies seek a more precise understanding of how their drugs interact with each amylin receptor. These results provide a foundation for the development of next-generation weight loss medications, with implications for obesity treatment and related research.
